🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseSurvodutide MASH Phase 2b — March 2026 Page 7

Survodutide MASH Phase 2b — March 2026

CanadaChris Fri, Aug 15, 2025 at 9:27 PM 31 replies 1,956 viewsPage 7 of 7
kevin_tulsa
Member
489
2,123
Jun 2024
Tulsa, OK
Sep 3, 2025 at 5:03 AM#31
hank_denver said:
If you are comparing against somebody else’s result, check that you are comparing the same measurement taken the same way.

Bookmarking. The distinction being drawn above is the one nobody else makes. Sending this to two other people who asked me the same thing last week.

Last edited: Sep 3, 2025 at 7:03 AM
37 10fiona_glasgow, Dr.RheumBOS, greg_boulder and 34 others
Reply Quote Save Share Report
MASHdoc_SA
Member
456
2,345
Aug 2024
San Antonio, TX
Sep 4, 2025 at 1:38 PM#32

Clinical perspective, offered as context rather than as advice. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.

38 11TrialTracker_MD, JennaRN, LabKate and 35 others
Reply Quote Save Share Report
Dr.SleepRoch
Senior Member
1,123
5,678
Apr 2024
Rochester, MN
Sep 5, 2025 at 10:12 PM#33
MASHdoc_SA said:
The useful move here is to separate what is established from what is widely repeated.

Same experience, arrived at from the opposite direction.

Last edited: Sep 6, 2025 at 2:12 AM
39 12Dr.NephBHM_UK, kim_atl_prep, sarah_TO and 36 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
jim_asheville
Member
289
1,234
Aug 2024
Asheville, NC
Sep 7, 2025 at 6:45 AM#34
MASHdoc_SA said:
The useful move here is to separate what is established from what is widely repeated.

There is a second half to this that has not been said yet. Take it one variable at a time. Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent argument can untangle them after the fact.

40 13wanda_boise, NurseAsh_DET, BenResearch_OR and 37 others
Reply Quote Save Share Report
Dr.PathRoch
Member
456
2,123
Jun 2024
Rochester, MN
Sep 8, 2025 at 3:17 PM#35

Adding the numbers, since they settle part of this. One habit that pays for itself: post the method alongside the number. A figure without its method cannot be checked, and an unchecked figure is how this community accumulates folklore.

Last edited: Sep 8, 2025 at 9:17 PM
41 14Dr.MetabolicMD, RetaRick_CA, JenPlateau and 38 others
Reply Quote Save Share Report
1567

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register